Buoyed by strong demand for its drug discovery services, Evotec SE expects both revenue and profit to increase by 15% this year while spending on research and development rises. In a conference call with analysts on 12 November, Werner Lanthaler, the chief executive, said the forecast reflected a strong order book extending well into 2020.
In the first nine months, revenue rose by 16% to €321.4 million and adjusted earnings before interest, taxes, depreciation and amortisations (EBITDA) was up by 36% at €93.2 million.